Another drug registration application submitted by a subsidiary of Fosun Pharmaceutical (02196) for furitinib succinate capsules was accepted by the State Drug Administration

Zhitongcaijing · 3d ago

Zhitong Finance App News, Fosun Pharmaceutical (02196) issued an announcement. Recently, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), the drug registration application submitted again for furitinib succinate capsules (project code: SAF-189, category 1; hereinafter referred to as “the new drug”) has been accepted by the State Drug Administration. The indication for this application is for partial late positive anaplastic lymphoma kinase (ALK) stage or metastatic non-small cell lung cancer ( NSCLC) treatment of patients.